Skip to main content

N0577 Phase III Integraoup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

NCT00887146

Phase III Integraoup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Associated Conditions

Brain Cancer

Principal Investigator

Sponsor

Alliance for Clinical Trials in Oncology

The purpose of this study is to compare the effectiveness of either 1) radiotherapy (RT, radiation therapy) along with temozolomide chemotherapy followed by additional temozolomide chemotherapy (RT + TMZ -> TMZ); or 2) radiotherapy followed by PCV chemotherapy [(RT -> PCV); PCV chemotherapy consists of three drugs, Matulane (procarbazine), Lomustine (CCNU) and Oncovin (vincristine)]; in the treatment of anaplastic glioma or low grade glioma with the 1p/19q codeletion. In this study, you will get one of the two possible treatments.

This study is currently enrolling.